IREN Limited reported strong AI cloud revenue growth and high segment margins in Q3, but still posted a net loss of $263 million with rising operating expenses. Delays from Microsoft and supply chain issues have pushed the $4 billion annual recurring revenue target to next year, while revenue growth lags behind cost increases. The company faces a $6 billion funding shortfall and is likely to dilute shares further as capital markets remain tight, keeping the stock rated as a Sell due to intensified dilution and debt risks.
IREN Limited's recent financial challenges provide context for readers interested in technology stocks. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 06, 2026 21:31 WIB: Among 150 priced US tech stocks, 81 rose and 68 fell today. Notably, TEAM dropped 14.62% to USD 156.50 with a typical hold time of 65 days and 88% buy orders, contrasting with CIFR which gained 12.61% to USD 6.25 and LRCX which rose 10.39% to USD 204.45, both with shorter hold times and higher sell activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
